{"id":100882,"date":"2026-07-10T01:56:24","date_gmt":"2026-07-10T01:56:24","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/100882\/"},"modified":"2026-07-10T01:56:24","modified_gmt":"2026-07-10T01:56:24","slug":"nurix-q2-revenue-9m-roche-deal-up-to-2-3b","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/100882\/","title":{"rendered":"Nurix Q2 revenue $9M; Roche deal up to $2.3B"},"content":{"rendered":"<p>Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a major global collaboration with Roche for BTK degrader bexobrutideg, worth up to $2.3 billion including a $700 million upfront payment.<\/p>\n<p>Q2 revenue was $9.0 million, net loss $89.5 million, and cash was $443.5 million, with pro-forma cash of about $1.14 billion including the expected Roche upfront.<\/p>\n<p>\n            Loading&#8230;\n          <\/p>\n<p>          Loading translation&#8230;<\/p>\n<p class=\"context-ai-disclaimer\">AI-generated analysis. <a href=\"https:\/\/www.stocktitan.net\/rhea-ai.html\" rel=\"nofollow noopener\" target=\"_blank\">How Rhea-AI works<\/a>. Not financial advice.<\/p>\n<p>          Positive<\/p>\n<p>                    Roche collaboration for bexobrutideg with up to $2.3 billion in potential payments, including $700 million upfront<\/p>\n<p>                    Pro-forma cash position of approximately $1.14 billion including expected Roche upfront payment<\/p>\n<p>                    Strong Phase 1a bexobrutideg data: 22.1-month median PFS and 83% ORR in relapsed\/refractory CLL\/SLL<\/p>\n<p>                    Phase 1b bexobrutideg ORR of 92.9% in Cohort 5 and 84.2% in Cohort 15<\/p>\n<p>                    Ongoing pivotal Phase 2 DAYBreak CLL-201 and planned Phase 3 DAYBreak CLL-306 trials<\/p>\n<p>                    $2 million research milestone payment earned from Sanofi in Q2 2026<\/p>\n<p>          Negative<\/p>\n<p>                    Quarterly revenue declined to $9.0 million from $44.1 million year over year<\/p>\n<p>                    Research and development expenses increased to $87.7 million from $78.1 million<\/p>\n<p>                    General and administrative expenses rose to $15.6 million from $14.3 million<\/p>\n<p>                    Net loss nearly doubled to $89.5 million from $43.5 million<\/p>\n<p>                    Cash, cash equivalents and marketable securities decreased to $443.5 million from $592.9 million as of prior fiscal year-end<\/p>\n<p class=\"context-narrative-text\">\n      The quarter pairs a landmark Roche deal with a $700M upfront and strong CLL ORRs with a wider $89.5M net loss and revenue drop to $9.0M. Investors may weigh sizable R&amp;D spend and elevated short positioning against the now pro-forma $1.14B cash base.\n    <\/p>\n<p>\n        Revenue<br \/>\n        $9.0M<\/p>\n<p>        Three months ended May 31, 2026 vs $44.1M in prior-year quarter<\/p>\n<p>\n        R&amp;D expenses<br \/>\n        $87.7M<\/p>\n<p>        Three months ended May 31, 2026 vs $78.1M in prior-year quarter<\/p>\n<p>\n        Net loss<br \/>\n        $89.5M<\/p>\n<p>        Three months ended May 31, 2026 vs $43.5M in prior-year quarter<\/p>\n<p>\n        Cash &amp; securities<br \/>\n        $443.5M<\/p>\n<p>        Cash, cash equivalents and marketable securities as of May 31, 2026<\/p>\n<p>\n        Pro-forma cash<br \/>\n        $1.14B<\/p>\n<p>        Including expected $700M Roche upfront payment<\/p>\n<p>\n        Roche upfront payment<br \/>\n        $700M<\/p>\n<p>        Upfront payment expected within 30 days of agreement effectiveness<\/p>\n<p>\n        ORR (Phase 1a)<br \/>\n        83%<\/p>\n<p>        Relapsed\/refractory CLL\/SLL; median progression-free survival 22.1 months<\/p>\n<p>\n        ORR (Phase 1b Cohort 5)<br \/>\n        92.9%<\/p>\n<p>        BTK inhibitor\u2013treated, BCL2 inhibitor\u2013na\u00efve CLL patients<\/p>\n<p>            Date<br \/>\n            Event<br \/>\n            Sentiment<br \/>\n            24h Move<br \/>\n            Catalyst<\/p>\n<p>            Apr 08<\/p>\n<p>                <a href=\"https:\/\/www.stocktitan.net\/news\/NRIX\/nurix-therapeutics-reports-first-quarter-2026-financial-results-and-hwv01t9c4h2u.html\" rel=\"nofollow noopener\" target=\"_blank\">Q1 2026 earnings<\/a><\/p>\n<p>              Positive<\/p>\n<p>              -4.6%<\/p>\n<p>              Reported Q1 2026 results with advancing DAYBreak trials and solid cash balance.<\/p>\n<p>            Jan 28<\/p>\n<p>                <a href=\"https:\/\/www.stocktitan.net\/news\/NRIX\/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2025-f0q6uucsxyf0.html\" rel=\"nofollow noopener\" target=\"_blank\">Q4 2025 earnings<\/a><\/p>\n<p>              Neutral<\/p>\n<p>              -1.6%<\/p>\n<p>              Q4 and FY2025 results featuring strong CLL data, higher losses, and $250M offering.<\/p>\n<p>            Oct 09<\/p>\n<p>                <a href=\"https:\/\/www.stocktitan.net\/news\/NRIX\/nurix-therapeutics-reports-third-quarter-2025-financial-results-and-n2i7a8g921gq.html\" rel=\"nofollow noopener\" target=\"_blank\">Q3 2025 earnings<\/a><\/p>\n<p>              Positive<\/p>\n<p>              -10.1%<\/p>\n<p>              Q3 2025 update with high ORR bexobrutideg data and pivotal study plans.<\/p>\n<p>            Jul 09<\/p>\n<p>                <a href=\"https:\/\/www.stocktitan.net\/news\/NRIX\/nurix-therapeutics-reports-second-quarter-2025-financial-results-and-2n21j8f1o40e.html\" rel=\"nofollow noopener\" target=\"_blank\">Q2 2025 earnings<\/a><\/p>\n<p>              Positive<\/p>\n<p>              -3.9%<\/p>\n<p>              Q2 2025 results with strong revenue growth, collaborations, and encouraging CLL data.<\/p>\n<p>            Apr 08<\/p>\n<p>                <a href=\"https:\/\/www.stocktitan.net\/news\/NRIX\/nurix-therapeutics-reports-first-quarter-2025-financial-results-and-zj55hz7ysv19.html\" rel=\"nofollow noopener\" target=\"_blank\">Q1 2025 earnings<\/a><\/p>\n<p>              Positive<\/p>\n<p>              +3.7%<\/p>\n<p>              Q1 2025 results highlighting growing collaboration revenue and expanding pipeline.<\/p>\n<p>        Pattern Detected<\/p>\n<p class=\"context-pattern-text\">Earnings updates have often seen the stock trade lower even when they paired solid clinical progress with a strong cash position.<\/p>\n<p>-3.3%<\/p>\n<p>        Average Historical Move<br \/>\n        earnings<\/p>\n<p class=\"context-narrative-text\">Across five prior earnings-style updates, the stock typically moved about -3.3%, often selling off despite constructive pipeline news. This quarter\u2019s mix of a major Roche deal and wider losses fits that tension between growth and near-term profitability.<\/p>\n<p class=\"context-narrative-text\">Recent earnings repeatedly showed Nurix deepening investment in bexobrutideg, moving from early data to pivotal plans while maintaining sizable cash balances, reinforcing a multi-year development focus over short-term earnings.<\/p>\n<p>            Short Interest<\/p>\n<p>21.26% of float<\/p>\n<p>\n              0%<br \/>\n              15%<br \/>\n              30%+\n            <\/p>\n<p>            moderate<\/p>\n<p>            as of 2026-06-15<\/p>\n<p>            Days to cover: 4.94<\/p>\n<p class=\"risk-short-note\">Short interest is elevated, suggesting that sentiment is cautious and that the stock may experience higher volatility and potential squeeze dynamics if newsflow sharply shifts expectations.<\/p>\n<p>          progression-free survival<\/p>\n<p>          medical<\/p>\n<p>&#8220;Updated Phase 1a results demonstrated: Median progression-free survival of 22.1 months&#8221;<\/p>\n<p>Progression-free survival is the length of time during and after a treatment that a patient&#8217;s disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential\u2014think of it as a stopwatch showing how long a therapy can keep the illness at bay.<\/p>\n<p>          objective response rate<\/p>\n<p>          medical<\/p>\n<p>&#8220;Objective response rate (ORR) of 83% Responses observed across difficult-to-treat&#8221;<\/p>\n<p>The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug\u2019s ability to produce a clear treatment effect\u2014like counting how many plants visibly respond after applying a new fertilizer\u2014and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.<\/p>\n<p>          accelerated approval<\/p>\n<p>          regulatory<\/p>\n<p>&#8220;pivotal Phase 2 trial designed to support a potential Accelerated Approval submission&#8221;<\/p>\n<p>Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company&#8217;s prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.<\/p>\n<p>          phase 1a\/1b<\/p>\n<p>          medical<\/p>\n<p>&#8220;ongoing NX-5948-301 Phase 1a\/1b study demonstrating durable responses&#8221;<\/p>\n<p>Phase 1a\/1b are the earliest human clinical trial stages that test a new drug\u2019s safety, how the body handles it, and the right dosage. Think of phase 1a as a careful test drive in healthy volunteers to find safe dosing, and phase 1b as expanded testing\u2014often in people with the target condition\u2014to confirm dosing and look for early signs the treatment works; investors watch these stages because they determine safety, dosing decisions, and the next funding or development milestones.<\/p>\n<p>          hart-scott-rodino antitrust improvements act<\/p>\n<p>          regulatory<\/p>\n<p>&#8220;including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act&#8221;<\/p>\n<p>A U.S. law that requires companies planning large mergers or acquisitions to notify federal antitrust authorities and wait for review before completing the deal. Think of it like applying for a building permit: regulators check whether the combined business would unfairly hurt competition and can clear the deal, impose changes, or seek to stop it, so the process affects transaction timing, cost, and whether expected benefits reach investors.<\/p>\n<p class=\"context-ai-disclaimer\">AI-generated analysis. <a href=\"https:\/\/www.stocktitan.net\/rhea-ai.html\" rel=\"nofollow noopener\" target=\"_blank\">How Rhea-AI works<\/a>. Not financial advice.<\/p>\n<p>    &#13;<br \/>\n&#13;<br \/>\n&#13;<\/p>\n<p>  <img decoding=\"async\" class=\"ps-bar__icon\" src=\"https:\/\/static.stocktitan.net\/img\/icons\/Google_News_icon.svg\" width=\"24\" height=\"24\" alt=\"\" loading=\"lazy\" aria-hidden=\"true\"\/><\/p>\n<p>&#13;<br \/>\n    &#13;<br \/>\n    See more from StockTitan in Google Search and AI answers.&#13;<br \/>\n    Adds StockTitan as a preferred source \u00b7 opens Google&#13;\n  <\/p>\n<p>&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<\/p>\n<p>      07\/09\/2026 &#8211; 04:01 PM<\/p>\n<p align=\"center\">Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment<\/p>\n<p align=\"center\">Co-development, co-commercialization collaboration includes comprehensive clinical development plan in malignant hematology and enables expansion of bexobrutideg into chronic spontaneous urticaria (CSU) and multiple sclerosis (MS)<\/p>\n<p align=\"center\">Presented clinical data update at the European Hematology Association (EHA) supporting bexobrutideg&#8217;s potential as a best-in-class BTK degrader across multiple lines of therapy in CLL<\/p>\n<p align=\"center\">Well capitalized with cash, cash equivalents and marketable securities\u00a0of $443.5 million as of May 31, 2026, and pro-forma cash of approximately $1.14 billion, including the expected $700 million upfront payment upon closing of the Roche collaboration<\/p>\n<p>BRISBANE, Calif., July  09, 2026  (GLOBE NEWSWIRE) &#8212; Nurix Therapeutics, Inc. (Nasdaq: <a href=\"https:\/\/www.stocktitan.net\/overview\/NRIX\/\" title=\"View NRIX stock overview\" class=\"symbol-link\" rel=\"nofollow noopener\" target=\"_blank\">NRIX<\/a>), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today reported financial results for the fiscal quarter ended May 31, 2026, and highlighted significant corporate updates including Nurix\u2019s entry into a global license and collaboration agreement with Roche for Nurix\u2019s potential best-in-class BTK degrader bexobrutideg (NX-5948), continued advancement of its registrational program in chronic lymphocytic leukemia (CLL), expansion into immunology and neurology, and progress across its broader pipeline.<\/p>\n<p>&#8220;The second quarter of 2026 was a defining period for Nurix and the targeted protein degradation field,&#8221; said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. &#8220;Our global collaboration with Roche, an industry leader, validates both the differentiated clinical profile of bexobrutideg in malignant hematology and its broader potential in immunology and inflammation. The co-development, co-commercialization structure of the agreement allows Nurix to pursue multiple opportunities in significant markets in both oncology and autoimmune disease with financial strength and global reach.&#8221;<\/p>\n<p>Program Highlights*<\/p>\n<p>Bexobrutideg Global Partnership with Roche<\/p>\n<p>  Nurix announced a global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology and neurology. Within 30 days following the effectiveness of the agreement, Nurix expects to receive a $700 million upfront payment and will be eligible to receive development, regulatory and commercial milestone payments for potential total payments of up to $2.3 billion, inclusive of the upfront payment. Development costs will be shared 40% by Nurix and 60% by Roche. Profits and losses in the United States will be shared equally and Nurix is eligible to receive tiered royalties on ex-U.S. sales.The collaboration includes a comprehensive development strategy spanning multiple hematologic malignancies and expansion into immune-mediated diseases, including planned Phase 2 studies in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU).The collaboration agreement is subject to customary closing conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other required antitrust clearances.  <\/p>\n<p>Bexobrutideg Clinical Data Presented at EHA 2026<\/p>\n<p>  Nurix reported new and updated clinical data from the ongoing NX-5948-301 Phase 1a\/1b study demonstrating durable responses and a favorable tolerability profile in patients with relapsed\/refractory CLL\/SLL.Updated Phase 1a results demonstrated:Median progression-free survival of 22.1 monthsObjective response rate (ORR) of 83%Responses observed across difficult-to-treat patient populations, including patients with BTK resistance mutations, high-risk molecular features and central nervous system involvement   New Phase 1b results demonstrated: ORR of 92.9% among evaluable patients with 18 of 19 patients remaining on treatment at data cutoff in Cohort 5, evaluating patients previously treated with a BTK inhibitor but na\u00efve to BCL2 inhibitor therapyORR of 84.2% among evaluable patients with 19 of 20 patients remaining on treatment at data cutoff in Cohort 15, evaluating BTKi-na\u00efve patients including treatment-na\u00efve patients   <\/p>\n<p>Bexobrutideg Clinical Development Program<\/p>\n<p>  Enrollment continues in DAYBreak CLL-201, the pivotal Phase 2 trial designed to support a potential Accelerated Approval submission in patients with relapsed\/refractory CLL whose disease has progressed following treatment with a covalent BTK inhibitor, a BCL2 inhibitor and a non-covalent BTK inhibitor.Preparations continue for DAYBreak CLL-306, the global randomized Phase 3 confirmatory trial evaluating bexobrutideg versus pirtobrutinib in patients with relapsed\/refractory CLL following prior BTK inhibitor therapy with the dosing of the first patient anticipated in mid-2026.Preparations continue for the Phase 1b\/2 Study Basket Combination Study to define optimal treatment regimens to support the initiation of combination pivotal trials in CLL and potentially mantle cell lymphoma (MCL) and Waldenstrom\u2019s macroglobulinemia (WM).Nurix continues to enroll select cohorts in the NX-5948-301 Phase 1a\/1b clinical trial <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05131022?term=nx-5948&amp;viewType=Card&amp;rank=3\" rel=\"nofollow noopener\" target=\"_blank\">(NCT05131022)<\/a> in patients with relapsed or refractory B cell malignancies. The Phase 1b study includes cohorts testing the safety and efficacy of the 600 mg dose of bexobrutideg in earlier lines of therapy in CLL patients and in NHL patients. Updated data from this study are anticipated to be presented at upcoming medical meetings throughout 2026. More information on the ongoing Phase 1a\/1b trial of bexobrutideg is available at <a href=\"https:\/\/www.clinicaltrials.gov\" rel=\"nofollow noopener\" target=\"_blank\">www.clinicaltrials.gov<\/a>.  <\/p>\n<p>Expansion of Bexobrutideg Development into Immunology and Neurology<\/p>\n<p>  Presented new preclinical and Phase 1 translational data from healthy volunteers at the 2026 Society for Investigative Dermatology Annual Meeting supporting the potential of bexobrutideg in chronic spontaneous urticaria. Data demonstrated potent and selective BTK degradation across key immune cell populations, robust degradation in blood and skin following oral administration of the new tablet formulation, and enhanced suppression of Fc\u03b5RI-driven biology compared with BTK inhibition.Continued advancement of a healthy volunteer SAD\/MAD study evaluating the new tablet formulation of bexobrutideg to support potential future development in immunology and neurology indications with planning underway for the initiation of Phase 2 trials in CSU and MS.  <\/p>\n<p>Broader Pipeline Highlights<\/p>\n<p>Preclinical Oncology Pipeline<\/p>\n<p>  Presented new data at the 2026 AACR Annual Meeting highlighting progress across multiple targeted protein degradation programs, including pan-mutant BRAF degrader NRX-0305, CBL-B program NX-1607 and AURKA degrader NRX-4972.Data reinforced the potential for targeted protein degradation to overcome key limitations of conventional therapeutic approaches, including treatment resistance and incomplete pathway suppression.  <\/p>\n<p>NX-1607<\/p>\n<p>  Nurix has completed enrollment of current Phase 1a dose escalation cohorts of NX-1607, an investigational oral CBL-B inhibitor, across multiple solid tumor oncology indications and is reviewing the data to determine next steps.  <\/p>\n<p>Zelebrudomide<\/p>\n<p>  Zelebrudomide is an orally bioavailable degrader of BTK and the cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) designed for the treatment of relapsed or refractory B-cell malignancies. Nurix has completed enrollment in the current dose escalation cohorts of the Phase 1 trial (NCT04830137) and is reviewing the data to determine next steps.   <\/p>\n<p>Strategic Collaborations<\/p>\n<p>  In addition to the Roche collaboration, Sanofi continues to advance the STAT6 degrader, NX-3911, in IND-enabling studies. Nurix retains the right to opt-in after clinical proof of concept to a 50\/50 U.S. profit share and co-development agreement. Gilead continues to advance the IRAK-4 degrader, GS-6791, in an ongoing first-in-human Phase 1 study in healthy volunteers. Nurix retains the right to opt-in after Phase 1 to a 50\/50 U.S. profit share and co-development, `subject to certain restrictions. Nurix and Pfizer continue to progress multiple preclinical degrader antibody conjugate (DAC) programs. In the second fiscal quarter of 2026, Nurix earned a $2 million milestone payment from Sanofi.  <\/p>\n<p>*Expected timing of events throughout this press release is based on calendar year quarters.<\/p>\n<p>Fiscal Second Quarter 2026 Financial Results<\/p>\n<p>Revenue\u00a0for the three months ended May 31, 2026, was $9.0 million compared with $44.1 million for the three months ended May 31, 2025. The decrease was primarily due to $30 million of license revenue from two Sanofi license extensions in the prior year. During the three months ended May 31, 2026, Nurix achieved a research milestone under its collaboration with Sanofi of $2 million.<\/p>\n<p>Research and development expenses\u00a0for the three months ended May 31, 2026, were $87.7 million compared with $78.1 million for the three months ended May 31, 2025. The increase was primarily related to clinical costs and contract manufacturing costs as Nurix continued to accelerate the enrollment of patients in the ongoing Phase 2 trial of bexobrutideg and to enable the initiation of Phase 3 trials.<\/p>\n<p>General and administrative expenses\u00a0for the three months ended May 31, 2026, were $15.6\u00a0million compared with $14.3 million for the three months ended May 31, 2025. The increase was primarily due to an increase in legal costs for collaboration and business development activities.<\/p>\n<p>Net loss\u00a0for the three months ended May 31, 2026, was $89.5 million or ($0.81) per share compared with $43.5 million or ($0.52) per share for the three months ended May 31, 2025.<\/p>\n<p>Cash, cash equivalents and marketable securities\u00a0were $443.5 million as of May 31, 2026, compared to $592.9 million as of November 30, 2025. In addition, we expect to receive the $700 million upfront payment from Roche in the third fiscal quarter of 2026.<\/p>\n<p>About Bexobrutideg<br \/>Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton\u2019s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology.<\/p>\n<p>Bexobrutideg is currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), and in the NX-5948-301 Phase 1a\/1b clinical trial (NCT05131022) in patients with relapsed or refractory B-cell malignancies. A new tablet formulation of bexobrutideg is also being evaluated in a first-in-human single-ascending-dose and multiple-ascending-dose study in healthy volunteers (NCT06717269) to support future development in immunology and neurology indications. Additional information about ongoing clinical trials can be found at clinicaltrials.gov.<\/p>\n<p>About Nurix Therapeutics, Inc.<br \/>Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix\u2019s clinical stage oncology pipeline includes degraders of Bruton\u2019s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix\u2019s autoimmune disease pipeline includes a clinical-stage degrader of IRAK-4 in collaboration with Gilead and preclinical stage degrader of STAT6 in collaboration with Sanofi. Nurix\u2019s broader drug discovery pipeline consists of a multiple additional wholly-owned programs as well as those under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix\u2019s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine\u2019s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OJ3mhuVOOmLt_oEA0PsNnSn_1B6CvD3e1evlVPI1Css7QlOJpdHYtXrkEepwkqYIxZspnz-3QLA3qGv_86WX96QSwgJohY7e-LVxwzlIA9Y=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.nurixtx.com<\/a>.<\/p>\n<p>Forward-Looking Statements<br \/>This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cshould,\u201d \u201cwill,\u201d and similar expressions and their variants, as they relate to Nurix, may identify forward-looking statements. All statements that reflect Nurix\u2019s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix\u2019s future financial or business performance; Nurix\u2019s future plans, prospects and strategies; Nurix\u2019s plans and expectations with respect to its current and prospective drug candidates; Nurix\u2019s plans and expectations with respect to the clinical trials for its drug candidates; the tolerability, safety profile, therapeutic potential and other advantages of Nurix\u2019s drug candidates; the planned timing and conduct of Nurix\u2019s clinical trials; the planned timing for the provision of updates and findings from Nurix\u2019s preclinical studies and clinical trials; the potential benefits of and Nurix\u2019s expectations with respect to its strategic collaborations; and the effectiveness of the Roche collaboration and receipt of the upfront payment and potential future milestone payments. Forward-looking statements reflect Nurix\u2019s current beliefs, expectations, and assumptions regarding the future of Nurix\u2019s business, its future plans and strategies, its development plans, its preclinical and clinical results, future conditions and other factors Nurix believes are appropriate in the circumstances. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix\u2019s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) whether Nurix will be able to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) uncertainties related to the timing and results of preclinical studies and clinical trials; (iii)\u00a0whether Nurix will be able to fund development activities and achieve development goals; (iv) uncertainties related to the timing and receipt of payments from Nurix\u2019s collaboration partners, including milestone payments and royalties on future product sales; (v) the impact of global business, political and macroeconomic conditions, cybersecurity events, instability in the banking system, and global events, including regional and military conflicts around the world, on Nurix\u2019s business, clinical trials, financial condition, liquidity and results of operations; (vi) whether Nurix will be able to protect intellectual property; (vii) the Roche Collaboration Agreement is subject to closing conditions, including antitrust clearances, and may not close when expected or at all; and (viii) other risks and uncertainties described under the heading \u201cRisk Factors\u201d in Nurix\u2019s Quarterly Report on Form 10-Q for the fiscal quarter ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.<\/p>\n<p>Contacts:<\/p>\n<p>Investors &amp; Media<br \/>Kris Fortner<br \/>Nurix Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=m1DNxKher8uS_SsjbnzjP5M_OZEpnp0x2XmrJ62Y_fmYjvoaknZfjfSu-UwydUiXy7mOD9GtzAUPcVI2z3rb0eQiqjBprC-e7W60FKtRpBQ=\" rel=\"nofollow noopener\" target=\"_blank\">kfortner@nurixtx.com<\/a><\/p>\n<p>&#8211;MORE&#8211;<\/p>\n<p> Nurix Therapeutics, Inc.Condensed Statements of Operations(in thousands, except share and per share amounts)(unaudited)\u00a0\u00a0Three Months Ended May 31,\u00a0Six Months Ended May 31,\u00a0\u00a02026\u00a0\u00a0\u00a02025\u00a0\u00a0\u00a02026\u00a0\u00a0\u00a02025\u00a0Revenue:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Collaboration revenue$9,043\u00a0\u00a0$14,056\u00a0\u00a0$15,295\u00a0\u00a0$32,509\u00a0License revenue\u00a0&#8211;\u00a0\u00a0\u00a030,000\u00a0\u00a0\u00a0&#8211;\u00a0\u00a0\u00a030,000\u00a0Total revenue\u00a09,043\u00a0\u00a0\u00a044,056\u00a0\u00a0\u00a015,295\u00a0\u00a0\u00a062,509\u00a0Operating expenses:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Research and development\u00a087,653\u00a0\u00a0\u00a078,096\u00a0\u00a0\u00a0171,789\u00a0\u00a0\u00a0147,759\u00a0General and administrative\u00a015,594\u00a0\u00a0\u00a014,282\u00a0\u00a0\u00a030,205\u00a0\u00a0\u00a025,936\u00a0Total operating expenses\u00a0103,247\u00a0\u00a0\u00a092,378\u00a0\u00a0\u00a0201,994\u00a0\u00a0\u00a0173,695\u00a0Loss from operations\u00a0(94,204)\u00a0\u00a0(48,322)\u00a0\u00a0(186,699)\u00a0\u00a0(111,186)Interest and other income, net\u00a04,398\u00a0\u00a0\u00a05,618\u00a0\u00a0\u00a09,719\u00a0\u00a0\u00a012,131\u00a0Loss before income taxes\u00a0(89,806)\u00a0\u00a0(42,704)\u00a0\u00a0(176,980)\u00a0\u00a0(99,055)Provision for (benefit from) income taxes\u00a0(271)\u00a0\u00a0760\u00a0\u00a0\u00a0(271)\u00a0\u00a0760\u00a0Net loss$(89,535)\u00a0$(43,464)\u00a0$(176,709)\u00a0$(99,815)Net loss per share, basic and diluted$(0.81)\u00a0$(0.52)\u00a0$(1.60)\u00a0$(1.19)Weighted-average number of shares outstanding, basic and diluted\u00a0111,084,423\u00a0\u00a0\u00a083,882,477\u00a0\u00a0\u00a0110,583,610\u00a0\u00a0\u00a083,723,403\u00a0  Nurix Therapeutics, Inc.<br \/>Condensed Balance Sheets<br \/>(in thousands)<br \/>(unaudited)<br \/>\u00a0\u00a0May 31,\u00a0November 30,\u00a0\u00a02026\u00a0\u00a0\u00a02025\u00a0Assets\u00a0\u00a0\u00a0Current assets:\u00a0\u00a0\u00a0Cash and cash equivalents$67,685\u00a0\u00a0$246,960\u00a0Marketable securities\u00a0375,844\u00a0\u00a0\u00a0345,981\u00a0Prepaid expenses and other current assets\u00a012,952\u00a0\u00a0\u00a013,878\u00a0Total current assets\u00a0456,481\u00a0\u00a0\u00a0606,819\u00a0Operating lease right-of-use assets\u00a050,107\u00a0\u00a0\u00a050,517\u00a0Property and equipment, net\u00a020,007\u00a0\u00a0\u00a022,490\u00a0Restricted cash\u00a0968\u00a0\u00a0\u00a0968\u00a0Other assets\u00a07,977\u00a0\u00a0\u00a07,341\u00a0Total assets$535,540\u00a0\u00a0$688,135\u00a0Liabilities and stockholders\u2019\u00a0equity\u00a0\u00a0\u00a0Current liabilities:\u00a0\u00a0\u00a0Accounts payable$12,208\u00a0\u00a0$11,215\u00a0Accrued expenses and other current liabilities\u00a043,267\u00a0\u00a0\u00a054,852\u00a0Operating lease liabilities, current\u00a03,221\u00a0\u00a0\u00a02,824\u00a0Deferred revenue, current\u00a013,324\u00a0\u00a0\u00a017,580\u00a0Total current liabilities\u00a072,020\u00a0\u00a0\u00a086,471\u00a0Operating lease liabilities, net of current portion\u00a054,922\u00a0\u00a0\u00a052,906\u00a0Deferred revenue, net of current portion\u00a05,971\u00a0\u00a0\u00a010,011\u00a0Total liabilities\u00a0132,913\u00a0\u00a0\u00a0149,388\u00a0Stockholders\u2019 equity:\u00a0\u00a0\u00a0Common stock\u00a0104\u00a0\u00a0\u00a0102\u00a0Additional paid-in-capital\u00a01,582,603\u00a0\u00a0\u00a01,541,766\u00a0Accumulated other comprehensive income (loss)\u00a0(145)\u00a0\u00a0105\u00a0Accumulated deficit\u00a0(1,179,935)\u00a0\u00a0(1,003,226)Total stockholders\u2019 equity\u00a0402,627\u00a0\u00a0\u00a0538,747\u00a0Total liabilities and stockholders\u2019 equity$535,540\u00a0\u00a0$688,135\u00a0  <img decoding=\"async\" loading=\"lazy\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/07\/1783648584_523_ti.gif\"\/> <br \/><img decoding=\"async\" loading=\"lazy\" alt=\"\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/07\/Nurix-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/><\/p>\n<p>      &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n  &#13;<br \/>\n&#13;<\/p>\n<p>&#13;<br \/>\n    FAQ  &#13;\n  <\/p>\n<p>&#13;<br \/>\n  &#13;<br \/>\n  &#13;<\/p>\n<p>        What did Nurix Therapeutics (NRIX) report for its fiscal Q2 2026 revenue and net loss?<\/p>\n<p>&#13;<br \/>\n          Nurix reported Q2 2026 revenue of $9.0 million and a net loss of $89.5 million. According to Nurix, revenue fell from $44.1 million a year earlier, while net loss widened from $43.5 million, reflecting higher R&amp;D and G&amp;A expenses.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What are the key terms of the Nurix (NRIX) global collaboration with Roche for bexobrutideg?<\/p>\n<p>&#13;<br \/>\n          The Roche deal includes up to $2.3 billion in potential payments, with a $700 million upfront. According to Nurix, development costs are shared 40% Nurix and 60% Roche, with equal U.S. profit sharing and tiered ex-U.S. royalties, pending customary antitrust clearances.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        How strong were the latest bexobrutideg CLL clinical results reported by Nurix (NRIX) in July 2026?<\/p>\n<p>&#13;<br \/>\n          Bexobrutideg showed an 83% ORR and 22.1-month median PFS in Phase 1a, and ORRs of 92.9% and 84.2% in Phase 1b cohorts. According to Nurix, responses occurred across difficult-to-treat relapsed\/refractory CLL\/SLL populations.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What is Nurix Therapeutics\u2019 (NRIX) cash position after the Roche bexobrutideg agreement?<\/p>\n<p>&#13;<br \/>\n          Nurix reported $443.5 million in cash, cash equivalents and marketable securities as of May 31, 2026. According to Nurix, pro-forma cash is about $1.14 billion when including the expected $700 million upfront payment from Roche in fiscal Q3 2026.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        How is Nurix (NRIX) advancing pivotal trials for bexobrutideg in CLL?<\/p>\n<p>&#13;<br \/>\n          Nurix is enrolling the pivotal Phase 2 DAYBreak CLL-201 trial and preparing the Phase 3 DAYBreak CLL-306 study. According to Nurix, CLL-306 will compare bexobrutideg versus pirtobrutinib in relapsed\/refractory CLL, with first patient dosing anticipated in mid-2026.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What other pipeline and collaboration milestones did Nurix (NRIX) highlight in its Q2 2026 update?<\/p>\n<p>&#13;<br \/>\n          Nurix reported progress on NX-1607, NRX-0305, NRX-4972 and zelebrudomide, plus partnered programs with Sanofi, Gilead and Pfizer. According to Nurix, it earned a $2 million milestone from Sanofi and continues multiple preclinical and early clinical degrader efforts.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<br \/>\n&#13;<br \/>\n&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a major global collaboration with Roche for BTK&hellip;\n","protected":false},"author":2,"featured_media":100883,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[41223,1115,41219,1627,41250,41221,134,27198,49866],"class_list":["post-100882","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-bexobrutideg","tag-biotech","tag-cll","tag-financial-results","tag-nrix","tag-nurix-therapeutics","tag-roche","tag-roche-collaboration","tag-second-quarter-results"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116893200341314825","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/100882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=100882"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/100882\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/100883"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=100882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=100882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=100882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}